<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538317</url>
  </required_header>
  <id_info>
    <org_study_id>2006-452</org_study_id>
    <nct_id>NCT00538317</nct_id>
  </id_info>
  <brief_title>GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction</brief_title>
  <acronym>AGIR2</acronym>
  <official_title>Comparison of Administration of Tirofiban in the Ambulance or in the Cathlab in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with acute myocardial infarction who are managed in the prehospital setting, and
      who will treated with primary angioplasty, we evaluate the benefit of an early administration
      of tirofiban, a powerful GPIIbIIIa inhibitors. Patients are randomised to early
      administration in the ambulance or administration in the cathlab. The primary endpoint is
      TIMI 2-3 flow in the first coronary opacification of the culprit artery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TIMI 2-3 flow on first coronary artery opacification</measure>
    <time_frame>start of coronarography</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protocol déviations of Tirofiban administration (no bolus, bolus decreasing or increasing of +/- 10% from expected value, dose perfusion decreasing or increasing of 1 ml/h from expected value, time perfusion &gt; 24h or &lt; 18h</measure>
    <time_frame>During tirofiban administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI 3, TIMI 2 and TIMI 1-0 flow frequency in responsible artery before and after angioplasty</measure>
    <time_frame>before and after angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular ejection fraction value</measure>
    <time_frame>during angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPK and troponin values (before and after angioplasty, peak and 24h after angioplasty)</measure>
    <time_frame>during 24h after angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reduction of ST segment elevation (considered as resoluted if amplitude decreasing &gt; 70%)</measure>
    <time_frame>after angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of following Serious Adverse Events: anginal recurrence, infarct recurrence, urgent revascularization, serious heart failure and hospital mortality</measure>
    <time_frame>During hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tirofiban bolus + perfusion started at the site of caring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tirofiban bolus + perfusion started at the beginning of coronarography (usual use of tirofiban)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tirofiban</intervention_name>
    <description>bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min</description>
    <arm_group_label>1</arm_group_label>
    <other_name>agrastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tirofiban</intervention_name>
    <description>bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min</description>
    <arm_group_label>2</arm_group_label>
    <other_name>agrastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Information given to the patient and consent obtained

          -  Thoracic pain or symptoms of infarction

          -  Symptoms &lt; 12 hours

          -  ST deviation identified by electrocardiography (ECG) in at least 2 contiguous leads

          -  Transfer time to angioplasty room evaluated by the coordinating doctor as less than 90
             minutes (from ECG diagnosis to arrival in angioplasty room)

        Exclusion criteria

          -  Physiological or pathological conditions not compatible with a revascularisation
             procedure (in the acute phase of myocardial infarction (MI)

          -  Administration of fibrinolytics or another antiGPIIBIIIa in the previous seven days

          -  Contraindications to aspirin or tirofiban or heparin

          -  Diagnosed severe kidney failure (dialysis, creatinin &gt; 350µmol/l

          -  Pregnancy

          -  Time for transfer to the angioplasty room evaluated by coordinating doctor as more
             than 90 minutes

          -  Subject participating in another trial

          -  Subject with high hemorrhagic risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Bonnefoy-Cudraz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>6900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>November 21, 2008</last_update_submitted>
  <last_update_submitted_qc>November 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Eric BONNEFOY-CUDRAZ, MD</name_title>
    <organization>Hospices Civils de Lyon</organization>
  </responsible_party>
  <keyword>Acute myocardial infarction,</keyword>
  <keyword>GPIIbIIIa inhibitors,</keyword>
  <keyword>primary angioplasty,</keyword>
  <keyword>tirofiban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirofiban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

